Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 149 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07204457RecruitingPhase 2/Phase 3
Meningococcal vaccine trial for healthy adults 19 to 55 years old
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
SeoulAges 19–55 - NCT07205926RecruitingPhase 1
Testing a new Shigella vaccine in healthy adults
This trial tests a new Shigella vaccine in healthy adults to see if it is safe and creates a good immune response. It is a first-in-human study, meaning this is the first time the vaccine is given to people.
Cincinnati, OhioAges 18–49 - NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT07221734RecruitingPhase 3
Testing MB11 versus Opdivo for advanced melanoma
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
FunchalAges 18 years+ - NCT07237464RecruitingPhase 1
Safety study of GB18 injection in healthy adults
This early-phase trial tests a new injection called GB18 in healthy adults to see if it is safe and how the body processes it. It may help researchers understand how to treat conditions that involve the immune system.
Beijing, Beijing MunicipalityAges 18–55 - NCT07252791RecruitingPhase 4
PCV20 vaccine study for kids and young adults with rheumatic diseases
This study tests if a pneumonia vaccine (PCV20) is safe and works well in children and young adults with certain autoimmune rheumatic diseases like juvenile arthritis, lupus, or dermatomyositis. It aims to help protect them from serious infections.
São Paulo, São PauloAges 2–25 - NCT07258745RecruitingPhase 1
Comparing a risankizumab biosimilar to Skyrizi in healthy adults
This study tests a new biosimilar medicine (CKD-704) to see how it compares to the approved Skyrizi treatments for healthy adults. It checks how the medicine moves through the body, its safety, and how the immune system responds.
Warsaw, WarszawaAges 18–55 - NCT07299955RecruitingPhase 1
Testing a new Herceptin shot in healthy men
This trial tests a new version of the breast cancer drug Herceptin (called Bmab3000) given as a single shot under the skin. It looks at how the drug moves through the body, its safety, and how the immune system responds, in healthy volunteers.
Christchurch, Main Building: 264 Antigua Street,Ages 18–65 - NCT07356050Recruiting
Measles vaccine study for children with sickle cell disease
This study checks if the measles vaccine works well in children with sickle cell disease. It aims to help protect children with this condition from measles.
Cincinnati, OhioAges 6 months–6 years - NCT07358156RecruitingPhase 1
Comparing a new dupilumab medicine to Dupixent in healthy adults
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
Berlin, State of BerlinAges 18–55 - NCT07379580RecruitingPhase 2
Test of an mRNA vaccine for mpox in Africa
This trial tests a new mRNA vaccine to prevent mpox. It looks at how safe and effective the vaccine is in adults who have or haven't been exposed to mpox or similar viruses before.
KinshasaAges 18–64 - NCT07400003RecruitingPhase 1/Phase 2
Shingles mRNA vaccine safety and immune response study
This trial tests a new mRNA vaccine to prevent shingles (herpes zoster). It checks if the vaccine is safe and helps your body build immunity. It's for adults aged 40 or older (phase 1) or 50+ (phase 2).
XinjiangAges 40 years+ - NCT07425821RecruitingPhase 1
Marburg Virus Vaccine Safety Trial
This trial tests a new vaccine to protect against Marburg virus, a rare but serious infection. The vaccine uses a weakened virus to teach your body to fight the Marburg virus, and researchers are checking if it is safe and how well it works.
Washington D.C., District of ColumbiaAges 18–50 - NCT07477587RecruitingPhase 1
Comparing two myeloma treatments for new patients
This trial tests a new drug combination (HLX15-SC) against an approved treatment (DARZALEX FASPRO) along with lenalidomide and dexamethasone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant.
Springdale, ArkansasAges 18 years+ - NCT07485855RecruitingPhase 3
Flu vaccine study for blood cancer patients
This trial tests how well the flu vaccine works in people with blood cancers like lymphoma, leukemia, or multiple myeloma. It aims to find the best vaccination strategy to protect you during treatment.
SeoulAges 19 years+ - NCT07467707RecruitingPhase 3
Chikungunya vaccine trial for teens and adults
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
Cebu City, CebuAges 12 years+ - NCT07500506RecruitingPhase 3
Safety of a fifth dose of the Lyme disease vaccine
This study is for people who have already received four doses of the Lyme vaccine (VLA15) in a previous study. It tests whether a fifth dose is safe and helps the body build more protection against Lyme disease.
Bangor, MaineAges 7 years+ - NCT07543744RecruitingPhase 1
Comparing RPH-030 to Vectibix for metastatic colorectal cancer
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
ArkhangelskAges 18 years+ - NCT07555392RecruitingPhase 2/Phase 3
Chikungunya Vaccine Safety and Immune Response Study
This study tests a new vaccine to protect against chikungunya virus, a disease spread by mosquitoes that causes fever and joint pain. The study measures how well your immune system responds to the vaccine and tracks any side effects.
Guwahati, AssamAges 12–65 - NCT07565090RecruitingPhase 1
Sudan Virus Vaccine Safety Study for Healthy Adults
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
Washington D.C., District of ColumbiaAges 18–50 - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07616934RecruitingPhase 1
Safety and immune response study of VAX-A1 vaccine in healthy young adults
This study tests a new vaccine called VAX-A1 in healthy people aged 18–40 to see if it's safe and if it helps the body build protection against Group A Streptococcus (a bacteria that can cause serious infections). You'll receive two vaccine doses and have blood tests and heart monitoring over 6 months.
Adelaide, South AustraliaAges 18–40 - NCT07667322RecruitingPhase 1
Study of a new under-the-skin multiple sclerosis treatment
This trial tests a new way to give ocrelizumab, an approved MS treatment, as a shot under the skin instead of through an IV. It aims to see if it's safe and works well for people with relapsing or primary progressive MS.
Carlsbad, CaliforniaAges 18–65
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 149 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.